MedTrace Logo

A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma

NCT07650266 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-08-11

No results posted yet for this study

Summary

The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.

Conditions

  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Cancer
  • Nasopharynx Carcinoma
  • Nasopharynx Cancer

Interventions

DRUG

Cemiplimab

Cemiplimab (LIBTAYO) is a PD-1 blocking antibody

DRUG

Fianlimab

Fianlimab is a fully human monoclonal antibody targeting the immune checkpoint receptor LAG-3 on T cells

Sponsors & Collaborators

Principal Investigators

  • Nancy Lee, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2030-07-31
Completion
2030-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07650266 on ClinicalTrials.gov